Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nedaplatin + gemcitabine versus cisplatin + gemcitabine as first-line therapy for advanced lung squamous cell carcinoma
ChiCTR-TRC-13004124Phase 4Completed
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Sep 2012
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of nedaplatin, gemcitabine, cisplatin and palonosetron in Pulmonary squamous cell carcinoma (2 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Progression-free survival. Started Sep 2012; status: completed.
02
Drugs
nedaplatingemcitabinecisplatinpalonosetron
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR-TRC-13004124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-13004124.